| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $30,616,312 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Fairmount Funds Management LLC | 1 | $30M | 0 | $0 | $30M | |
| Mahoney Stephen F. | President and CEO | 1 | $499,262 | 0 | $0 | $499,262 |
| Beetham Thomas W. | Chief Operating Officer | 1 | $117,050 | 0 | $0 | $117,050 |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Over the last 12 months, insiders at Viridian Therapeutics, Inc. have bought $30.62M and sold $0 worth of Viridian Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Viridian Therapeutics, Inc. have bought $13.52M and sold $4.43M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fairmount Funds Management LLC () — $30M. Mahoney Stephen F. (President and CEO) — $499,262. Beetham Thomas W. (Chief Operating Officer) — $117,050.
The last purchase of 21,400 shares for transaction amount of $499,262 was made by Mahoney Stephen F. (President and CEO) on 2024‑09‑27.
| 2024-09-27 | Mahoney Stephen F. | President and CEO | 21,400 0.0284% | $23.33 | $499,262 | -28.53% | ||
| 2024-09-27 | Beetham Thomas W. | Chief Operating Officer | 5,000 0.0066% | $23.41 | $117,050 | -28.53% | ||
| 2024-09-13 | Fairmount Funds Management LLC | 1.6M 2.1285% | $18.75 | $30M | -22.76% | |||
| 2024-01-22 | Fairmount Funds Management LLC | See Remarks | 476,190 0.9578% | $21.00 | $10M | -11.30% | ||
| 2023-06-16 | Sale | Meisner Lara | Chief Legal Officer | 27 <0.0001% | $28.35 | $765 | -34.59% | |
| 2023-06-15 | Sale | Meisner Lara | Chief Legal Officer | 2,269 0.0054% | $28.02 | $63,577 | -36.35% | |
| 2023-06-06 | Sale | Meisner Lara | Chief Legal Officer | 5,126 0.0121% | $25.02 | $128,253 | -28.07% | |
| 2023-06-05 | Sale | Meisner Lara | Chief Legal Officer | 499 0.0012% | $25.03 | $12,490 | -27.62% | |
| 2023-06-02 | Sale | Meisner Lara | Chief Legal Officer | 1,875 0.0044% | $24.21 | $45,394 | -25.76% | |
| 2023-04-12 | Myers Scott Dunseth | Chief Executive Officer | 4,000 0.01% | $25.37 | $101,479 | -24.18% | ||
| 2023-03-13 | Myers Scott Dunseth | 5,500 0.0137% | $29.15 | $160,324 | -32.01% | |||
| 2023-03-09 | Sale | Meisner Lara | General Counsel and Secretary | 29,971 0.0733% | $29.07 | $871,257 | -33.06% | |
| 2023-02-02 | Sale | Violin Jonathan | Chief Executive Officer | 50,000 0.1224% | $36.80 | $1.84M | -41.33% | |
| 2023-01-23 | Sale | Meisner Lara | General Counsel and Secretary | 6,843 0.0169% | $35.66 | $244,021 | -37.40% | |
| 2023-01-17 | Sale | Katz Barrett | Chief Medical Officer | 24,853 0.0607% | $37.21 | $924,780 | -40.15% | |
| 2023-01-10 | Sale | Katz Barrett | Chief Medical Officer | 47,377 0.1162% | $35.30 | $1.67M | -35.58% | |
| 2022-12-21 | Sale | Meisner Lara | General Counsel and Secretary | 16,326 0.0503% | $29.19 | $476,556 | -19.67% | |
| 2022-12-16 | Sale | Meisner Lara | General Counsel and Secretary | 1,297 0.0041% | $28.44 | $36,887 | -14.56% | |
| 2022-12-14 | Sale | Meisner Lara | General Counsel and Secretary | 15,656 0.0491% | $28.12 | $440,247 | -14.61% | |
| 2022-11-15 | Sale | Meisner Lara | General Counsel and Secretary | 8,125 0.0244% | $22.05 | $179,156 | +8.41% |
| Fairmount Funds Management LLC | 3445813 4.2232% | $57.86M | 3 | 0 | +15.96% | |
| Mahoney Stephen F. | President and CEO | 21400 0.0262% | $359,306.00 | 1 | 0 | |
| Beetham Thomas W. | Chief Operating Officer | 6000 0.0074% | $100,740.00 | 1 | 0 | |
| Frazier Life Sciences Public Fund, L.P. | 10 percent owner | 1505200 1.8448% | $25.27M | 1 | 0 | +25.75% |
| Fairmount Healthcare Fund II L.P. | 1363764 1.6714% | $22.9M | 1 | 0 | +8.69% | |
| Booth Bruce | director | 1351090 1.6559% | $22.68M | 1 | 0 | +6.91% |
| Logos Global Master Fund LP | 10 percent owner | 550000 0.6741% | $9.23M | 2 | 0 | +5.96% |
| Violin Jonathan | Chief Executive Officer | 480905 0.5894% | $8.07M | 0 | 9 | |
| LEFKOFF KYLE | director | 463473 0.568% | $7.78M | 0 | 9 | |
| Riccitelli Samuel D | President & CEO | 345130 0.423% | $5.79M | 2 | 0 | |
| Myers Scott Dunseth | Chief Executive Officer | 259500 0.318% | $4.36M | 2 | 0 | <0.0001% |
| Meisner Lara | Chief Legal Officer | 29971 0.0367% | $503,213.09 | 0 | 11 | |
| Hughes Thomas E. | director | 12827 0.0157% | $215,365.33 | 1 | 1 | <0.0001% |
| Levy Adam Scott | Chief Business Officer | 10540 0.0129% | $176,966.60 | 2 | 0 | +4.18% |
| Katz Barrett | Chief Medical Officer | 0 0% | $0 | 0 | 2 |
$831,902,292 | 108 | 9.34% | $1.2B | |
$11,583,737 | 45 | 49.75% | $1.48B | |
$100,002,191 | 42 | 21.48% | $1.21B | |
$530,111,731 | 35 | 8.69% | $1.27B | |
$148,770,544 | 34 | 80.63% | $1.5B | |
$309,951,506 | 30 | 32.56% | $1.55B | |
$1,295,059 | 29 | 102.78% | $1.53B | |
$149,456,352 | 27 | -8.77% | $1.21B | |
$99,922,809 | 23 | 28.37% | $1.36B | |
$92,580,864 | 14 | -1.28% | $1.43B | |
Viridian Therapeutics, Inc. (VRDN) | $43,198,628 | 12 | -0.10% | $1.37B |
$20,499,451 | 9 | 71.54% | $1.35B | |
$32,575,266 | 8 | 37.03% | $1.75B | |
$107,098,946 | 7 | 1.61% | $1.6B | |
$107,703,099 | 7 | 29.71% | $1.22B | |
$91,325,021 | 6 | 1.83% | $1.32B | |
$21,792,890 | 6 | 75.72% | $1.76B | |
$46,235,722 | 6 | -31.77% | $1.24B | |
$5,000,000 | 1 | -22.84% | $1.65B |
| Increased Positions | 95 | +47.5% | 11M | +11.73% |
| Decreased Positions | 86 | -43% | 10M | -10.81% |
| New Positions | 27 | New | 3M | New |
| Sold Out Positions | 28 | Sold Out | 2M | Sold Out |
| Total Postitions | 209 | +4.5% | 92M | +0.92% |
| Fmr Llc | $161,832.00 | 14.49% | 11.88M | +698,434 | +6.25% | 2024-12-31 |
| Blackrock, Inc. | $77,744.00 | 6.96% | 5.71M | -50,467 | -0.88% | 2025-03-31 |
| Vanguard Group Inc | $62,585.00 | 5.6% | 4.6M | +174,952 | +3.96% | 2024-12-31 |
| Deep Track Capital, Lp | $61,600.00 | 5.52% | 4.52M | +771,796 | +20.58% | 2024-12-31 |
| Vr Adviser, Llc | $52,882.00 | 4.74% | 3.88M | 0 | 0% | 2024-12-31 |
| State Street Corp | $47,977.00 | 4.3% | 3.52M | +1M | +48.02% | 2024-12-31 |
| Fairmount Funds Management Llc | $46,932.00 | 4.2% | 3.45M | 0 | 0% | 2024-12-31 |
| Kynam Capital Management, Lp | $45,304.00 | 4.06% | 3.33M | +814,967 | +32.45% | 2024-12-31 |
| Tang Capital Management Llc | $33,954.00 | 3.04% | 2.49M | +250,000 | +11.15% | 2024-12-31 |
| Commodore Capital Lp | $32,688.00 | 2.93% | 2.4M | -150,124 | -5.89% | 2024-12-31 |